BindingDB logo
myBDB logout

38 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27597413 58 Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.EBI Southern Medical University
27301679 21 Design and synthesis of potent and selective pyridazin-4(1H)-one-based PDE10A inhibitors interacting with Tyr683 in the PDE10A selectivity pocket.EBI Takeda Pharmaceutical Company Limited
26789933 100 Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases.EBI Intra-Cellular Therapies, Inc.
26935942 41 Synthesis and evaluation of analogs of the phenylpyridazinone NPD-001 as potent trypanosomal TbrPDEB1 phosphodiesterase inhibitors and in vitro trypanocidals.EBI Mercachem
26526739 35 Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.EBI Southern Medical University
25815146 29 Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors.EBI Janssen Pharmaceutica N.V.
25801159 36 Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.EBI CSIR-Indian Institute of Integrative Medicine
25456383 113 Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility.EBI TBA
25221665 33 Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement.EBI Janssen Pharmaceutica NV
24392688 31 Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator.EBI Pfizer Inc.
23806553 7 Discovery of triazines as potent, selective and orally active PDE4 inhibitors.EBI BioCrea GmbH
23651455 1 Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand.EBI Pfizer Inc.
23260348 91 Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.EBI Janssen-Cilag S.A.
23137303 38 Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5.EBI Chinese Academy of Sciences
22834877 119 Current landscape of phosphodiesterase 10A (PDE10A) inhibition.EBI Pfizer Inc.
22401864 61 Discovery of oxazole-based PDE4 inhibitors with picomolar potency.EBI Merck Research Laboratories
15887951 29 The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.EBI Monash University (Parkville Campus)
22142545 96 Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia.EBI Merck Research Laboratories
21988093 316 Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.EBI Pfizer Inc.
21983442 142 Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors.EBI biocrea GmbH
21570840 44 Synthesis and SAR development of novel P2X7 receptor antagonists for the treatment of pain: part 1.EBI Merck Research Laboratories
21189023 66 Synthesis and molecular modeling of novel tetrahydro-ß-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties.EBI German University in Cairo
20450197 80 Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.EBI Biotie Therapies GmbH
19631533 126 Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.EBI Pfizer Global Research and Development
19919087 55 Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.EBI Pfizer Global Research and Development
18976905 35 Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction.EBI Chong Kun Dang Research Institute
17683932 55 Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitors.EBI Schering-Plough Research Institute
16275071 26 A new chemical tool for exploring the physiological function of the PDE2 isozyme.EBI Pfizer, Inc.
16263279 37 A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.EBI Pfizer, Inc.
15837326 51 Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.EBI Schering-Plough Research Institute
12668004 53 Design, synthesis and biological activity of beta-carboline-based type-5 phosphodiesterase inhibitors.EBI Pfizer Global Research and Development
22284362 91 Identification of biologically active PDE11-selective inhibitors using a yeast-based high-throughput screen.BDB Boston College